Reproducibility of Serologic Assays for Influenza Virus A (H5N1)

0301 basic medicine 572 Infectious and parasitic diseases RC109-216 immunogenicity Antibodies, Viral World Health Organization Communicable Diseases Communicable Diseases, Emerging Antibodies 03 medical and health sciences serologic assays Neutralization Tests vaccine Influenza, Human Influenza A Virus Animals Humans viruses False Positive Reactions Serologic Tests Viral Emerging Sheep Influenza A Virus, H5N1 Subtype pandemic Research R Reproducibility of Results Hemagglutination Inhibition Tests Reference Standards Influenza 3. Good health Influenza Vaccines Medicine H5N1 Subtype influenza Laboratories Human
DOI: 10.3201/eid1508.081754 Publication Date: 2009-08-19T16:50:45Z
ABSTRACT
Hemagglutination-inhibition (HI) and neutralization are used to evaluate vaccines against influenza virus A (H5N1); however, poor standardization leads to interlaboratory variation of results. A candidate antibody standard (07/150) was prepared from pooled plasma of persons given clade 1 A/Vietnam/1194/2004 vaccine. To test human and sheep antiserum, 15 laboratories used HI and neutralization and reassortant A/Vietnam/1194/2004, A/turkey/Turkey/1/2005 (clade 2.2), and A/Anhui/1/2005 (clade 2.3.4) viruses. Interlaboratory variation was observed for both assays, but when titers were expressed relative to 07/150, overall percentage geometric coefficient of variation for A/Vietnam/1194/2004 was reduced from 125% to 61% for HI and from 183% to 81% for neutralization. Lack of reduced variability to clade 2 antigens suggested the need for clade-specific standards. Sheep antiserum as a standard did not reliably reduce variability. The World Health Organization has established 07/150 as an international standard for antibody to clade 1 subtype H5 and has an assigned potency of 1,000 IU/ampoule.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (20)
CITATIONS (112)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....